PMID- 35765281
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 24
IP  - 2
DP  - 2022 Aug
TI  - Absolute lymphocyte count and C-reactive protein-albumin ratio can predict 
      prognosis and adverse events in patients with recurrent esophageal cancer treated 
      with nivolumab therapy.
PG  - 257
LID - 10.3892/ol.2022.13377 [doi]
LID - 257
AB  - Predicting the prognosis and adverse events (AEs) of nivolumab therapy for 
      recurrent esophageal cancer is very important. The present study investigated 
      whether a simple blood biochemical examination could be used to predict prognosis 
      and AEs following nivolumab treatment for relapse of esophageal cancer. A total 
      of 41 patients who received nivolumab treatment for recurrent esophageal cancer 
      after esophagectomy were analyzed. The absolute lymphocyte count (ALC), 
      neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), 
      monocyte-lymphocyte ratio (MLR) and C-reactive protein-albumin ratio (CAR) were 
      assessed at the time of nivolumab induction as indices that can be calculated by 
      blood biochemical examinations alone. Median values were 1,015 for ALC, 3.401 for 
      NLR, 242.6 for PLR, 0.458 for MLR and 0.119 for CAR, and patients were divided 
      into two groups according to values. A high ALC, low NLR, low PLR, low MLR and 
      low CAR were associated with a better response to nivolumab. In addition, 
      patients with the aforementioned indices, with the exception of low PLR, or 
      better response were more likely to develop AEs in univariate analysis. In 
      multivariate analysis, a high ALC [odds ratio (OR): 4.857, P=0.043] and low CAR 
      (OR: 9.099, P=0.004) were identified as independent risk factors for AEs. 
      Survival analysis revealed that overall survival and progression-free survival 
      (PFS) rates after nivolumab treatment differed significantly between the high and 
      low groups of ALC, NLR, PLR, MLR and CAR. The multivariate analysis identified a 
      low ALC [hazard ratio (HR): 3.710, P=0.003] and high CAR (HR: 2.953, P=0.007) as 
      independent poor prognostic factors of PFS. In conclusion, ALC and CAR have 
      potential as biomarkers for outcomes of recurrent esophageal cancer following 
      nivolumab treatment.
CI  - Copyright: (c) Inoue et al.
FAU - Inoue, Hiroyuki
AU  - Inoue H
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Shiozaki, Atsushi
AU  - Shiozaki A
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Fujiwara, Hitoshi
AU  - Fujiwara H
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Konishi, Hirotaka
AU  - Konishi H
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Kiuchi, Jun
AU  - Kiuchi J
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Ohashi, Takuma
AU  - Ohashi T
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Shimizu, Hiroki
AU  - Shimizu H
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Arita, Tomohiro
AU  - Arita T
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Yamamoto, Yusuke
AU  - Yamamoto Y
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Morimura, Ryo
AU  - Morimura R
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Kuriu, Yoshiaki
AU  - Kuriu Y
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Ikoma, Hisashi
AU  - Ikoma H
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Kubota, Takeshi
AU  - Kubota T
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Okamoto, Kazuma
AU  - Okamoto K
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Otsuji, Eigo
AU  - Otsuji E
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural 
      University of Medicine, Kyoto 602-8566, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220614
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC9219019
OTO - NOTNLM
OT  - C-reactive protein-albumin ratio
OT  - absolute lymphocyte count
OT  - nivolumab
OT  - recurrent esophageal cancer
OT  - survival analysis
COIS- The authors declare that they have no competing interests.
EDAT- 2022/06/30 06:00
MHDA- 2022/06/30 06:01
PMCR- 2022/06/14
CRDT- 2022/06/29 01:53
PHST- 2022/01/15 00:00 [received]
PHST- 2022/05/20 00:00 [accepted]
PHST- 2022/06/29 01:53 [entrez]
PHST- 2022/06/30 06:00 [pubmed]
PHST- 2022/06/30 06:01 [medline]
PHST- 2022/06/14 00:00 [pmc-release]
AID - OL-24-02-13377 [pii]
AID - 10.3892/ol.2022.13377 [doi]
PST - epublish
SO  - Oncol Lett. 2022 Jun 14;24(2):257. doi: 10.3892/ol.2022.13377. eCollection 2022 
      Aug.